

# First Reported Nosocomial Outbreak Of NDM-5-Producing *Klebsiella pneumoniae* In A Neonatal Unit In China

This article was published in the following Dove Press journal:  
*Infection and Drug Resistance*

Ziyan Kong<sup>1,\*</sup>  
Rui Cai<sup>1,\*</sup>  
Chen Cheng<sup>1</sup>  
Chuanling Zhang<sup>2</sup>  
Haiquan Kang<sup>3</sup>  
Ping Ma<sup>3</sup>  
Bing Gu<sup>1,3</sup>

<sup>1</sup>Medical Technology School, Xuzhou Medical University, Xuzhou, Jiangsu Province, People's Republic of China;

<sup>2</sup>Department of Laboratory Medicine, XuZhou Children's Hospital, Xuzhou, Jiangsu Province, People's Republic of China; <sup>3</sup>Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, People's Republic of China

\*These authors contributed equally to this work

**Purpose:** Carbapenem-resistant *Klebsiella pneumoniae* (CRKP) have emerged worldwide and also being a major threat to children and neonate. In this study, we describe a nosocomial outbreak of NDM-5-producing *Klebsiella pneumoniae* in neonatal unit of a teaching hospital in China from September 2015 to September 2016.

**Patients and methods:** We collected 12 carbapenem-resistant *K. pneumoniae* outbreak strains from 12 newborns and characterized these isolates for their antimicrobial susceptibility, clone relationships, and multi-locus sequence types using vitek-2 compact system, pulsed-field gel electrophoresis (PFGE) and multi-locus sequence typing (MLST). Resistant genes were detected by using PCR and sequencing. Plasmid conjugation experiment was carried out to determine the transferability of carbapenem resistance. PCR-based replicon typing (PBRT), S1 nuclease-PFGE, and southern blotting were conducted for plasmid profiling.

**Results:** All 12 *K. pneumoniae* isolates were resistant to carbapenems and carried *bla*<sub>NDM-5</sub>, *bla*<sub>TEM-1</sub> and *bla*<sub>SHV-11</sub>. Furthermore, PFGE analysis showed that NDM-5-producing *K. pneumoniae* were clonally related and MLST assigned them to sequence type 337. Conjugative assays showed that plasmids harboring *bla*<sub>NDM-5</sub> gene were self-transmissible. Plasmid analysis suggested that all *bla*<sub>NDM-5</sub> gene located on a ~45 kb IncX3 type plasmid.

**Conclusion:** To the best of our knowledge, this is the first report of a clone outbreak of *bla*<sub>NDM-5</sub>-carrying *K. pneumoniae* isolates from neonates. There is an urgent need for effective infection control measures to prevent *bla*<sub>NDM-5</sub> variants from becoming epidemic in the neonates in the future.

**Keywords:** *Klebsiella pneumoniae*, carbapenemases, *bla*<sub>NDM-5</sub>, ST337, neonate, IncX3

## Introduction

The continuous emergence of Carbapenem-resistant *Klebsiella pneumoniae* (CRKP) has become a serious public-health problem worldwide.<sup>1</sup> Among the newly emerging carbapenemases, New Delhi metallo- $\beta$ -lactamase (NDM) has been considered as a major clinical challenge due to its ability to hydrolyzing all  $\beta$ -lactams antibiotics except monobactams and its rapid spread worldwide.<sup>2</sup> Since NDM-1 was first identified in a *K. pneumoniae* isolate from a Swedish patient who had traveled to New Delhi in 2008,<sup>3</sup> 21 new *bla*<sub>NDM</sub> alleles have been discovered in global.<sup>4</sup> The rapid evolution of *bla*<sub>NDM</sub> genes represents a huge challenge for clinical infection treatment. In 2011, NDM-5 was first identified in a multidrug-resistant *Escherichia coli* isolate in the UK.<sup>5</sup> The NDM-5 enzyme differs from the prevalent NDM-1 at the amino acid positions, which appears to confer elevated

Correspondence: Bing Gu  
Department of Laboratory Medicine,  
Affiliated Hospital of Xuzhou Medical  
University, Xuzhou 221006, People's  
Republic of China  
Tel +8615862163560  
Email gb20031129@163.com

resistance to carbapenems and extended-spectrum cephalosporins. Unlike the prevalent NDM-1 enzyme, the identification of NDM-5 enzymes is not common. Among the *Enterobacteriaceae*, reports of *bla*<sub>NDM-5</sub>-harboring *K. pneumoniae* isolates are sporadic.<sup>6–12</sup> In this study, we investigate an outbreak of *bla*<sub>NDM-5</sub>-positive *K. pneumoniae* strains in neonatal unit of a teaching hospital in China with the aim of determining the molecular basis of the emerging ST337 carbapenem-resistant *K. pneumoniae* isolates responsible for this outbreak. As far as we know, this is the first description of NDM-5-producing *K. pneumoniae* nosocomial outbreak in the neonatal ward.

## Materials And Methods

### Collection Of Clinical Isolates And Patients

The study was conducted in the Department of Neonatology at a teaching hospital in Jiangsu Province, China. There are 120 beds in the Department of Neonatology, with an estimated population of 5000 patient visits per year. From September 2015 to September 2016, 12 non-duplicated strains of carbapenem-resistant *K. pneumoniae* were isolated from inpatients in newborn medicine ward. Strain identification was performed by Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS; Bruker Daltonik GmbH, Bremen, Germany). In vitro antimicrobial susceptibility testing of isolates was analyzed with VITEK-2 compact system (bioMérieux, Marcy-l'Étoile, France). The electronic medical records of the newborns including patient demographics, neonatal birth information, antimicrobial treatment, and clinical outcomes were retrospectively reviewed.

### Antimicrobial Susceptibility Testing

The minimum inhibitory concentrations (MICs) of meropenem (MEM), imipenem (IPM), aztreonam (ATM), ceftazidime (CAZ), cefepime (FEP), cefotaxime (CTX), amoxicillin-clavulanate (AMC), sulbactam/cefoperazone (SCF), piperacillin-tazobactam (TZP), amikacin (AM), levofloxacin (LE), ciprofloxacin (CPFX), compound Sulfamethoxazole (SMZ-TMP), tigecycline (TG) and polymyxin B (PB) were measured by broth microdilution method. Antimicrobial susceptibility testing was interpreted in accordance with the Clinical and Laboratory Standards Institute (CLSI),<sup>13</sup> except for sulbactam/cefoperazone, tigecycline and colistin, which were interpreted based on the

European Committee for Antimicrobial Susceptibility Testing (EUCAST) criteria.<sup>14</sup>

### Polymerase Chain Reaction (PCR) Amplifications And Sequencing

PCR using the primers mentioned in Table 1 allowed the detection of carbapenemase genes (*bla*<sub>KPC</sub>, *bla*<sub>NDM</sub>, *bla*<sub>VIM</sub>, *bla*<sub>OXA-48</sub> and *bla*<sub>IMP</sub>),<sup>15–19</sup> common extended-spectrum β-lactamase (ESBL) genes (*bla*<sub>CTX-M-1group</sub>, *bla*<sub>CTX-M-2group</sub>, *bla*<sub>CTX-M-8 group</sub>, *bla*<sub>CTX-M-9 group</sub>, *bla*<sub>SHV</sub> and *bla*<sub>TEM</sub>) and AmpC genes (*bla*<sub>CIT</sub>, *bla*<sub>MOX</sub>, *bla*<sub>DHA</sub>, *bla*<sub>EBC</sub>, and *bla*<sub>FOX</sub>).<sup>20,21</sup> DNA templates were prepared by alkaline lysis method using the kit (MoBio, USA). Amplifications were carried out in 50 μL final volume with 2 μL DNA, 25 μL 2X Taq Master Mix (TaKaRa, Dalian, China), and 2 μM of each primer (Shanghai Sangon, Shanghai, China). PCR conditions for all genes consisted of one cycle at 95°C for 5 mins, followed by 30 cycles at 94°C for 1 min, 72°C for 1 min, and one cycle at 72°C for 5 mins; the annealing step varied depending on the target gene as follows: 55°C/1 min for *bla*<sub>IMP</sub>; 59°C/1 min for *bla*<sub>KPC</sub>, *bla*<sub>VIM</sub>, *bla*<sub>CTX-M-2group</sub>, *bla*<sub>MOX</sub>; 58°C/1 min for *bla*<sub>NDM</sub>, *bla*<sub>CTX-M-8group</sub>, *bla*<sub>TEM</sub>; 62°C/1 min for *bla*<sub>OXA-48</sub>, *bla*<sub>CTX-M-1group</sub>, *bla*<sub>DHA</sub>, *bla*<sub>FOX</sub>; 64°C/1 min for *bla*<sub>CTX-M-9group</sub> and *bla*<sub>EBC</sub>; 66°C/1 min for *bla*<sub>CIT</sub>; 68°C/1 min for *bla*<sub>SHV</sub>. Amplified genes were screened by electrophoresis on a 1.5% agarose gel. The positive amplicons were subjected to direct sequencing, and the sequences obtained were compared to reported sequences from GenBank ([www.ncbi.nlm.nih.gov/GenBank](http://www.ncbi.nlm.nih.gov/GenBank)) using BLAST searches.

### Molecular Typing

The clonal relationships of the NDM-5 producing *K. pneumoniae* isolates were analyzed using Pulsed-field gel electrophoresis (PFGE) and whole genomic DNA was digested with XbaI restriction endonuclease (TaKaRa, Dalian, China). *Salmonella enterica* serotype Braenderup H9812 was used as a marker. The PFGE patterns were compared using BioNumerics software version 5.10, with a cutoff at 90% similarity to indicate identical PFGE types (pulsotypes). Multi-locus sequence typing was also performed for genotyping. Seven housekeeping genes (*infB*, *pgi*, *mdh*, *phoE*, *gapA*, *tonB* and *rpoB*) were amplified by using primer sequences described on the MLST website.<sup>22</sup> Sequence types (STs) were assigned using the MLST database (<http://bigsd.b.pasteur.fr/klebsiella/klebsiella.html>).

**Table 1** Primers Used For Amplification Of The Resistance Genes Of *K. pneumoniae* In This Study

Resistance Gene	Primer	Size Of PCR Product (bp)	References
<i>bla<sub>KPC</sub></i>	F: ATG TCA CTG TAT CGC CGT C R: TTA CTG CCC GTT GAC GCC	882	15
<i>bla<sub>NDM</sub></i>	F: GAAGCTGAGCACCGCATTAG R: GGGCCGTATGAGTGATTGC	982	16
<i>bla<sub>VIM</sub></i>	F: GCMCTTCTCGCGGAGATTGA R: TGCGCAGCACCRGGATAGA	257	17
<i>bla<sub>OXA-48</sub></i>	F: TTGGTGGCATCGATTATCGG R: GAGCACTTCTTTTGATGGC	743	18
<i>bla<sub>IMP</sub></i>	F: CTACCGCAGCAGAGTCTTTG R: AACCAGTTTTGCCTTACCAT	587	19
<i>bla<sub>CTX-M1group</sub></i>	F: CAGCGCTTTTGCCGTCTAAGC F: GGCCCATGGTAAAAAATCACTGC	945	20
<i>bla<sub>CTX-M2 group</sub></i>	F: CTC AGA GCA TTC GCC GCT CA R: CCG CCG CAG CCA GAA TAT CC	848	20
<i>bla<sub>CTX-M8group</sub></i>	F: ACTTCAGCCACACGGATTCA R: CGA GTA CGT CAC GAC GAC TT	1024	20
<i>bla<sub>CTX-M9group</sub></i>	F: GTTACAGCCCTTCGGCGATGATTC R: GCGCATGGTGACAAAGAGAGTGCAA	881	20
<i>bla<sub>SHV</sub></i>	F: CGCCGGGTTATTCTTATTTGTCGC R: TCT TTCCGATGCCGCCGCCAGTCA	1017	20
<i>bla<sub>TEM</sub></i>	F: ATA AAATTCTTGAAGACGAAA R: GACAGTTACCAATGCTTAATCA	1080	20
<i>bla<sub>CIT</sub></i>	F: TGGCCAGAACTGACAGGCAA R: TTTCTCCTGAACGTGGCTGG	462	21
<i>bla<sub>MOX</sub></i>	F: GCTGCTCAAGGAGCACAGGAT R: CACATTGACATAGGTGTGGTGC	520	21
<i>bla<sub>DHA</sub></i>	F: AACTTTACAGGTGTGCTGGGT R: CCGTACGCATACTGGCTTTGC	405	21
<i>bla<sub>EBC</sub></i>	F: TCGGTAAAGCCGATGTTGCGG R: CTTCCACTGCGGCTGCCAGTT	302	21
<i>bla<sub>FOX</sub></i>	F: AACATGGGGTATCAGGGAGATG R: CAAAGCGCGTAACCGGATTGG	190	21

## Conjugation Assay

A conjugation assay was performed between the isolates harboring *bla<sub>NDM-5</sub>* as donors and *E. coli* 600 (rifampicin-resistant strain) as a recipient.<sup>23</sup> Transconjugants were selected on Brain Heart Infusion agar containing 600 µg/mL rifampicin and 2 µg/mL imipenem for 24 hrs at 35°C and the presence of the *bla<sub>NDM-5</sub>* gene was confirmed by PCR sequencing. Susceptibility testing of the transconjugants was performed as well.

## Plasmid Analysis

Plasmid incompatibility types of the transconjugants were identified by PCR-based replicon typing as reported previously.<sup>24,25</sup> S1-PFGE and Southern blotting were performed to isolate and localize the resistant plasmid carrying *bla<sub>NDM-5</sub>* gene. Briefly, *bla<sub>NDM-5</sub>* positive isolates embedded in gold agarose gel plugs were digested with S1 nuclease (TaKaRa Biotechnology, Dalian, China) and plasmid DNA was electrophoresed on a CHEF-mapper XA (PFGE)

system (Bio-Rad, USA). Subsequently, the DNA fragments were blotted onto a positive-charged nylon membrane (Millipore, USA) and hybridized with *bla*<sub>NDM-5</sub> specific probe according to the protocol of DIG High Prime DNA Labeling and Detection Starter Kit I (Roche Applied Sciences, Penzberg, Germany).

# Results

## Clinical Characteristics Of 12 *K. pneumoniae*

*pneumoniae*  
In September 2015, a premature baby was born in this hospital with neonatal pneumonia and neonatal respiratory distress syndrome (case 1). The first carbapenem-resistant *K. pneumoniae* strain was isolated from the sputum culture on September 10, 2015. The first baby's mother suffered from acute gastroenteritis in the 7th month of pregnancy and hospitalized in another hospital in Jiangsu. After 1 day, another neonate also had neonatal respiratory distress syndrome and was positive for carbapenem-resistant *K. pneumoniae* in sputum culture. No other isolates were detected between October and November. However, since December 2015, the isolation rate of the strain has increased significantly, and 10 strains have been isolated from December 2015 to September 2016. By September 2016, 12 cases had occurred in newborn medicine ward in total. All the 12 neonates were improved after receiving various antimicrobial therapies including moxalactam, ceftazidime, cefotaxime, amoxicillin-sulbactam, amoxicillin-clavulanate and piperacillin-tazobactam. The 12 NDM-5-positive *K. pneumoniae* strains were detected from urine (n=1), blood (n=2) and sputum (n=9), respectively. Eleven newborns had neonatal pneumonia, three had neonatal respiratory distress syndrome, and two neonatal sepsis. Four newborns were premature, one of whom were very low birth weight infant. The demographic and clinical profiles of the 12 newborns involved in the outbreak of NDM-5-positive *K. pneumoniae* isolates are shown in Table 2.

## Antibiotic Susceptibility Testing And Detection Of Resistance Determinants

All 12 clinical isolates exhibited resistance to meropenem, imipenem, aztreonam, cefotaxime, ceftazidime, cefepime, sulbactam-cefoperazone, amoxicillin-clavulanate and piperacillin-tazobactam but remained susceptible to levofloxacin, ciprofloxacin, amikacin, compound sulfamethoxazole, tigecycline and polymixin B. All 12 isolates carried the *bla*<sub>NDM-5</sub>, *bla*<sub>SHV-11</sub>, and *bla*<sub>TEM-1</sub> genes. The other

Table 2 Clinical Features Of The Neonates In This Study

Case	Sex	Pregnancy Duration (wk)	Birth wt (g)	Dates Of Hospital Stay	Date Isolate Identified	Specimen	Type(s) Of Infections	Antimicrobial Therapy	Clinical Outcome
1	M	35	3000	1 Sep–17 Sep 2015	10 Sep 2015	Sputum	NP, NRDS	MOX	Improvement
2	M	36	1600	2 Sep–28 Sep 2015	11 Sep 2015	Sputum	NRDS	MOX+CAZ	Improvement
3	M	40	3400	18 Dec 2015–13 Jan 2016	23 Dec 2015	Sputum	NP	CAZ	Improvement
4	F	42	3100	22 Dec 2015–6 Jan 2016	24 Dec 2015	Sputum	NP	CTX	Improvement
5	M	39	3500	30 Dec 2015–8 Jan 2016	31 Dec 2015	Sputum	NP	MOX+AMS	Improvement
6	F	40	3300	29 Dec 2015–7 Jan 2016	1 Jan 2016	Urine	NP	MOX+AMS	Improvement
7	F	40	3300	18 Jan –7 Feb 2016	26 Jan 2016	Sputum	NP	MOX+AMS	Improvement
8	M	39	3450	7 Feb –14 Mar 2016	8 Mar 2016	Blood	NP, NS	MOX +AMC	Improvement
9	F	38	3300	20 Jul–2 Aug 2016	29 Jul 2016	Sputum	NP, NRDS	CAZ	Improvement
10	M	34	1500	22 Aug–2 Oct 2016	27 Aug 2016	Sputum	NP, NRDS	CAZ+TZP	Improvement
11	M	35	2590	3 Sep–14 Sep 2016	4 Sep 2016	Sputum	NP	CAZ	Improvement
12	F	40	3000	10 Sep–20 Sep 2016	18 Sep 2016	Blood	NP, NS	MOX +AMC	Improvement

Abbreviations: M, male; F, female; NP, neonatal pneumonia; NRDS, neonatal respiratory distress syndrome; NS, neonatal sepsis; MOX, moxalactam; CAZ, ceftazidime; CTX, cefotaxime; AMS, amoxicillin-sulbactam; AMC, amoxicillin-clavulanate; TZP, piperacillin-tazobactam.

resistance genes present in clinical *K. pneumoniae* isolates were not detected. The antibiotic resistance characteristics of the 12 NDM-5-positive *K. pneumoniae* isolates and their corresponding transconjugants are shown in Table 3.

## Molecular Typing

PFGE typing revealed that all 12 *K. pneumoniae* isolates in this outbreak shared highly similar PFGE patterns, which suggests that the 12 isolates were clonally related (Figure 1). MLST analysis showed that these 12 strains, KP1–12, belonged to ST337 with the allelic profile 2-1-11-1-1-1-13.

## Conjugation And Plasmid Analysis

In our study, all of plasmids carried *bla*<sub>NDM-5</sub> gene from the donor carbapenem-resistant *K pneumoniae* strains were successfully transferred to the recipient *Escherichia coli* EC600. The corresponding transconjugants are termed EC600-1–EC600-12, respectively. The MIC values of 12 the transconjugants were tested, and all transconjugants exhibited resistance to carbapenem and enzyme inhibitors (Table 3). As shown in Figure 2, S1-PFGE and Southern blot hybridization using a DIG-labeled *bla*<sub>NDM-5</sub> with incompatibility group-specific probe revealed that *bla*<sub>NDM-5</sub> was located on the nearly same size (~45 kb) IncX3 plasmids.

## Discussion

Carbapenem-resistant *Enterobacteriaceae* are an emerging problem, which spreads among our most vulnerable populations, children.<sup>26</sup> Many carbapenem resistance genes, such as *bla*<sub>KPC-2</sub>,<sup>21</sup> *bla*<sub>NDM-1</sub>,<sup>27</sup> *bla*<sub>OXA-48</sub>,<sup>28</sup> *bla*<sub>OXA-232</sub> and *bla*<sub>IMP-38</sub>,<sup>29,30</sup> have been found in *K. pneumoniae* outbreak strains in the newborn. Although NDM-1 enzyme was previously reported as the most prevalent type of carbapenemase in children,<sup>31</sup> our current results suggested that the emergence of NDM-5-producing *K. pneumoniae* caused nosocomial outbreak in neonatal unit. Our research team previously found high prevalence of *bla*<sub>NDM-5</sub> variants among carbapenem-resistant *E. coli* in Northern Jiangsu Province.<sup>32</sup> Based on analysis of previous articles, this is the first identification of *bla*<sub>NDM-5</sub>-harboring *K pneumoniae* outbreak strains in the neonatal infection. In this study, we aimed to identify the microbial resistance characteristics and transmission mechanism of CPKP infections caused by NDM-5-producing *K. pneumoniae* isolates, which may help to prevent the *bla*<sub>NDM-5</sub> from becoming epidemic in neonates.

Previous study found that premature birth and very low birth weight are associated with neonatal nosocomial infections with carbapenem-resistant *Enterobacteriaceae*.<sup>33</sup> In this study, 33.3% and 8.3% of the 12 newborns had premature birth and very low birth weight, respectively. During the study period, 7.0% and 3.15% of all patients in the neonatal unit had premature birth and very low birth weight, respectively. Newborns at high risk should be of the greatest concern in the future when performing procedures to prevent CRKP infection. Compared to adults, children have more limited therapeutic options.<sup>34</sup> In our study, all the clinical strains were susceptible to tigecycline and colistin in vitro. However, tigecycline is not recommended for children due to the risk of dental staining and colistin is not currently used in clinical treatment of children in China. Besides, aminoglycosides and fluoroquinolones are also rarely used for children due to their nephrotoxicity and ototoxicity.<sup>35</sup> Clinical data show that all the 12 neonates were improved after receiving various antimicrobial therapies including moxalactam, ceftazidime, cefotaxime, amoxicillin, sulbactam, amoxicillin-clavulanate and piperacillin-tazobactam. In this study, 12 newborns responded to treatment with these agents, which seems inconsistent with the antibiotic resistance characteristics of the clinical isolates. We assumed when these agents are combined, synergistic bactericidal action against pathogens may be achieved in vivo.<sup>36</sup> The isolates detected from sputum samples were presumed to be the flora colonized in the respiratory tract rather than the real infectious pathogen.


PFGE analysis showed that 12 clinical strains shared highly similar PFGE patterns in this outbreak. This implied that the outbreak of NDM-5-producing *K. pneumoniae* was because of clone spread and the first newborn might be the source of this outbreak. The first baby's mother was hospitalized for acute gastroenteritis during pregnancy and had high-risk factors for intrauterine infection. Although the NDM-5-producing *K. pneumoniae* strain was not detected from the mother, we assumed that a small number of these strains might potentially have been colonized in the mother's body and infected the fetus through the fetal circulation. Then, the CRKP isolate spread among patients in the neonatal ward, more research would be needed to uncover it in the future. It is noteworthy that *bla*<sub>NDM-5</sub> were not only reported in clinical specimens but also in hospital environmental such as the incubator water and the sharing of breast milk.<sup>37,38</sup> Hence, we cannot deny that the hospital environment may be the diffusion reservoirs of NDM-5-producing bacteria. Regrettably, the origin of the NDM-5-producing strains in our study is still unknown. Personal contact

Table 3 Antibiotic Resistance Characteristics Of The 12 NDM-5-Positive *K. pneumoniae* Isolates And Their Corresponding Transconjugants

Isolate No.	Antimicrobial Resistance Genes	Minimum Inhibitory Concentration (µg/mL)											
		MEM	IPM	ATM	CTX	CAZ	FEP	AM	CPFX	LE	AMC	TZP	SCF
KP1	bla <sub>NDM-5</sub> , SHV-11, TEM-1	8	≥ 16	≥ 64	≥ 64	≥ 64	≥ 32	≤ 2	0.5	1	≥ 32	≥ 128	≥ 64
KP2	bla <sub>NDM-5</sub> , SHV-11, TEM-1	≥ 16	≥ 16	16	≥ 64	≥ 64	≥ 32	≤ 2	≤ 0.25	≤ 0.12	≥ 32	≥ 128	≥ 64
KP3	bla <sub>NDM-5</sub> , SHV-11, TEM-1	≥ 16	≥ 16	≥ 64	≥ 64	≥ 64	≥ 32	≤ 2	1	1	≥ 32	≥ 128	≥ 64
KP4	bla <sub>NDM-5</sub> , SHV-11, TEM-1	≥ 16	≥ 16	≥ 64	≥ 64	≥ 64	≥ 32	≤ 2	0.5	1	≥ 32	≥ 128	≥ 64
KP5	bla <sub>NDM-5</sub> , SHV-11, TEM-1	≥ 16	≥ 16	≥ 64	≥ 64	≥ 64	≥ 32	≤ 2	≤ 0.25	≤ 0.12	≥ 32	≥ 128	≥ 64
KP6	bla <sub>NDM-5</sub> , SHV-11, TEM-1	≥ 16	≥ 16	≥ 64	≥ 64	≥ 64	≥ 32	≤ 2	0.5	1	≥ 32	≥ 128	≥ 64
KP7	bla <sub>NDM-5</sub> , SHV-11, TEM-1	≥ 16	≥ 16	≥ 64	≥ 64	≥ 64	≥ 32	≤ 2	0.5	1	≥ 32	≥ 128	≥ 64
KP8	bla <sub>NDM-5</sub> , SHV-11, TEM-1	≥ 16	≥ 16	≥ 64	≥ 64	≥ 64	≥ 32	≤ 2	1	1	≥ 32	≥ 128	≥ 64
KP9	bla <sub>NDM-5</sub> , SHV-11, TEM-1	≥ 16	≥ 16	≥ 64	≥ 64	≥ 64	≥ 32	≤ 2	0.5	1	≥ 32	≥ 128	≥ 64
KP10	bla <sub>NDM-5</sub> , SHV-11, TEM-1	8	≥ 16	≥ 64	≥ 64	≥ 64	≥ 32	≤ 2	≤ 0.25	≤ 0.25	≥ 32	≥ 128	≥ 64
KP11	bla <sub>NDM-5</sub> , SHV-11, TEM-1	≥ 16	≥ 16	≥ 64	≥ 64	≥ 64	≥ 32	≤ 2	0.5	1	≥ 32	≥ 128	≥ 64
KP12	bla <sub>NDM-5</sub> , SHV-11, TEM-1	≥ 16	≥ 16	≥ 64	≥ 64	≥ 64	≥ 32	≤ 2	0.5	1	≥ 32	≥ 128	≥ 64
EC600-1	bla <sub>NDM-5</sub>	8	≥ 16	≤ 1	≥ 64	≥ 64	4	≤ 2	≤ 0.25	≤ 0.12	≥ 32	≥ 128	≥ 64
EC600-2	bla <sub>NDM-5</sub>	8	8	≤ 1	≥ 64	≥ 64	4	≤ 2	0.5	≤ 0.12	≥ 32	≥ 128	≥ 64
EC600-3	bla <sub>NDM-5</sub>	8	≥ 16	≤ 1	≥ 64	≥ 64	4	≤ 2	≤ 0.25	≤ 0.12	≥ 32	≥ 128	≥ 64
EC600-4	bla <sub>NDM-5</sub>	≥ 16	≥ 16	≤ 1	≥ 64	≥ 64	8	≤ 2	0.5	≤ 0.12	≥ 32	≥ 128	≥ 64
EC600-5	bla <sub>NDM-5</sub>	8	≥ 16	≤ 1	≥ 64	≥ 64	8	≤ 2	0.5	≤ 0.12	≥ 32	≥ 128	≥ 64
EC600-6	bla <sub>NDM-5</sub>	≥ 16	≥ 16	≤ 1	≥ 64	≥ 64	8	≤ 2	0.5	≤ 0.12	≥ 32	≥ 128	≥ 64
EC600-7	bla <sub>NDM-5</sub>	4	≥ 16	≤ 1	≥ 64	≥ 64	8	≤ 2	0.5	≤ 0.12	≥ 32	≥ 128	≥ 64
EC600-8	bla <sub>NDM-5</sub>	≥ 16	≥ 16	≤ 1	≥ 64	≥ 64	4	≤ 2	≤ 0.25	≤ 0.12	≥ 32	≥ 128	≥ 64
EC600-9	bla <sub>NDM-5</sub>	4	≥ 16	≤ 1	≥ 64	≥ 64	4	≤ 2	0.5	≤ 0.12	≥ 32	≥ 128	≥ 64
EC600-10	bla <sub>NDM-5</sub>	8	≥ 16	≤ 1	≥ 64	≥ 64	4	≤ 2	≤ 0.25	≤ 0.12	≥ 32	≥ 128	≥ 64
EC600-11	bla <sub>NDM-5</sub>	4	≥ 16	≤ 1	≥ 64	≥ 64	8	≤ 2	0.5	≤ 0.12	≥ 32	≥ 128	≥ 64
EC600-12	bla <sub>NDM-5</sub>	8	≥ 16	≤ 1	≥ 64	≥ 64	4	≤ 2	≤ 0.25	≤ 0.12	≥ 32	≥ 128	≥ 64
EC600		≤ 1	≤ 1	≤ 1	≤ 1	≤ 1	≤ 1	≤ 2	≤ 0.25	≤ 0.12	2	2	2

Abbreviations: MEM, meropenem; IPM, imipenem; ATM, aztreonam; CAZ, ceftazidime; CTX, cefotaxime; FEP, cefepime; AM, amikacin; CPFX, ciprofloxacin; LE, levofloxacin; AMC, amoxicillin-clavulanate; TZP, piperacillin/tazobactam; SCF, sulfactam/cefoperazone; SMZ-TMP, compound Sulfamethoxazole; TG, tigecycline; PB, polymyxin B.






**Figure 1** Dendrogram of PFGE profiles of 12 *bla*<sub>NDM-5</sub>-positive *Klebsiella pneumoniae* isolates.

between the caregivers and the newborns hospitalized in the same ward is the most likely route of the transmission of the isolates. Hospital infection department took strict measures to control the outbreak in the hospital. First, pre-screening of carbapenem-resistant *Enterobacteriaceae* (CRE) in sputum samples and rectal swabs were introduced before admission to the neonatal medical ward. Second, strict isolation procedures were implemented for patients with CRE infection. Third, it was necessary for medical staff who contact with patients infected with CRE to go through a disinfection procedure. Finally, the neonatal medical wards where newborns with CRE infection stayed were thoroughly sterilized after the discharge of the patients. The sterilized ward left unoccupied for more than 2 weeks before new patients were admitted. Since the implementation of these strict measures in this neonatal medical ward, no infections due to ST337 NDM-5-producing *K. pneumoniae* isolates have occurred as of May 2017.

Several countries, such as India (ST648),<sup>39</sup> Denmark (ST1284),<sup>40</sup> Poland (ST418),<sup>41</sup> Spain (ST418),<sup>42</sup> Japan (ST540),<sup>43</sup> and Singapore (ST231),<sup>10</sup> have reported infections caused by NDM-5-positive strains since the initial



**Figure 2** *bla*<sub>NDM-5</sub>-carrying plasmid analysis (Top: SI-nuclease PFGE patterns; Bottom: Southern hybridization of the *bla*<sub>NDM-5</sub> probe, which was hybridized to the roughly 45 kb plasmid to confirm the presence of the resistant plasmid in the 12 ST337 carbapenem-resistant *K. pneumoniae* strains). Lane M: marker (*Salmonella* H9812); KP1 to KP12: *Klebsiella pneumoniae* outbreak strains.

identification of this carbapenemase type in UK (ST648).<sup>5</sup> In China, ST167 carbapenemase-producing *Escherichia coli* is main reservoir of *bla*<sub>NDM-5</sub>.<sup>44</sup> This is the first identification of NDM-5-producing *K. pneumoniae* isolate belonged to ST337, which related to CC37, and have only been identified in KPC-2-producing *K. pneumoniae* in carbapenem-resistant *Enterobacteriaceae* family.

The conjugation experiment showed that the carbapenem resistance phenotype of the 12 clinical isolates could be successfully transferred to the recipient strain EC600. All 12 transconjugants only carried the *bla*<sub>NDM-5</sub>, and the *bla*<sub>SHV-11</sub> and *bla*<sub>TEM-1</sub> were not detected. The plasmid analysis showed that all *bla*<sub>NDM-5</sub> were located on the IncX3 plasmids of the same size (with approximate size 45 kb). Notably, IncX3-type plasmids of 45 kb carrying *bla*<sub>NDM-5</sub> genes have been identified in India,<sup>6</sup> Australia and Denmark.<sup>38,39</sup> Furthermore, previous studies revealed that the IncX3-type plasmids played a significant role in the dissemination of the *bla*<sub>NDM-5</sub> gene among *Enterobacteriaceae* in China.<sup>45</sup> Therefore, there is an urgent need to adopt effective measures to control the spread of this resistant plasmid type.

Although international travel previously reported contributed to the global spread of NDM enzyme,<sup>3</sup> all patients in our study who carry *bla*<sub>NDM-5</sub> gene have never been

abroad. It was assumed that these NDM-5-producing isolates were autochthonous clones that had obtained the plasmid carrying *bla*<sub>NDM-5</sub>.<sup>44</sup> Notably, recent studies in China have revealed that NDM-5-producing *Enterobacteriaceae* was identified from pigs, dairy cows, and vegetables.<sup>46–48</sup> And, animals and plants were already important sources of drug-resistant strains. There is an urgent need for more epidemiological studies in the future to better understand mechanisms of emergence and dissemination of *bla*<sub>NDM-5</sub> gene in China.

## Conclusion

Our study first described the outbreak of ST337 NDM-5-producing *K. pneumoniae* isolates from neonates in China. Moreover, these outbreak strains were also detected to carry *bla*<sub>SHV-11</sub> and *bla*<sub>TEM-1</sub>. Their resistance profile may help pediatricians promote the prudent use of antibiotics in child health care. Worldwide surveillance of these ST337 NDM-5 producing *K. pneumoniae* isolates from neonates and implementation of stricter control measures are urgently needed to prevent these multiple-resistant strains from further disseminating in neonatal ward.

## Ethical Approval

Clinical research ethics committee of the Affiliated Hospital of Xuzhou Medical University approved the study as all samples collected in this work were initially used to diagnose for patient care without increasing the patient's medical costs and suffering.

## Acknowledgments

This research was supported by the National Natural Science Foundation of China (81871734, 81471994), Jiangsu Provincial Natural Science Foundation (BK20151154), Jiangsu Provincial Medical Talent (ZDRCA2016053), Six Talent Peaks Project of Jiangsu Province (WSN-135), and Advanced Health Talent of Six-One Project of Jiangsu Province (LGY2016042).

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Tzouvelekis LS, Markogiannakis A, Psychogiou M, et al. Carbapenemases in *Klebsiella pneumoniae* and other *Enterobacteriaceae*: an evolving crisis of global dimensions. *Clin Microbiol Rev*. 2012;25(4):682–707.
2. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. *Lancet Infect Dis*. 2010;10(9):597–602. doi:10.1016/S1473-3099(10)70143-2
3. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-β-lactamase gene, *bla*<sub>NDM-1</sub>, and a novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. *Antimicrob Agents Chemother*. 2009;53(12):5046–5054. doi:10.1128/AAC.00774-09
4. Liu L, Feng Y, McNally A, Zong Z. *Bla*<sub>NDM-21</sub>, a new variant of *bla*<sub>NDM</sub> in an *Escherichia coli* clinical isolate carrying *bla*<sub>CTX-M-55</sub> and *rmtB*. *J Antimicrob Chemother*. 2018;73(9):2336–2339. doi:10.1093/jac/dky226
5. Hornsey M, Phee L, Wareham DW, Novel Variant A. NDM-5, of the New Delhi metallo-β-lactamase in a multidrug-resistant *Escherichia coli* ST648 isolate recovered from a patient in the United Kingdom. *Antimicrob Agents & Chemother*. 2011;55(12):5952–5954. doi:10.1128/AAC.05108-11
6. Krishnaraju M, Kamatchi C, Jha AK, et al. Complete sequencing of an IncX3 plasmid carrying *bla*<sub>NDM-5</sub> allele reveals an early stage in the dissemination of the *bla*<sub>NDM</sub> gene. *Indian J Med Microbiol*. 2015;33(1):30–38. doi:10.4103/0255-0857.148373
7. Liu P, Liu Y, Wang L, Wei -D-D, Wan L-G. Draft genome sequence of an NDM-5-producing *Klebsiella pneumoniae* sequence type 14 strain of serotype K2. *Genome Announc*. 2016;4(2):e01610–e01615. doi:10.1128/genomeA.01610-15
8. Du H, Chen L, Tang Y, Kreiswirth BN. Correspondence emergence of the mcr-1 colistin resistance gene in carbapenem-resistant. *Lancet Infect Dis*. 2016;16(3):287–288. doi:10.1016/S1473-3099(16)00056-6
9. Shin J, Baek Y, Cho Y, et al. *bla*<sub>NDM-5</sub>-bearing IncFII-type plasmids of *Klebsiella pneumoniae* sequence type 147 transmitted by cross-border transfer of a patient. *Antimicrob Agents Chemother*. 2016;60(3):1932–1934. doi:10.1128/AAC.02722-15
10. Balm MND, La M, Krishnan P, Jureen R, Lin RTP, Teo JWP. Emergence of *Klebsiella pneumoniae* co-producing NDM-type and OXA-181 carbapenemases. *Clin Microbiol Infect*. 2013;19(9):E421–E423. doi:10.1111/1469-0691.12247
11. Bathoorn E, Rossen JW, Lokate M, Friedrich AW, Hammerum AM. Isolation of an NDM-5-producing ST16 *Klebsiella pneumoniae* from a Dutch patient without travel history abroad, August 2015. *Euro Surveill*. 2015;20:41. doi:10.2807/1560-7917.ES.2015.20.41.30040
12. Li A, Yang Y, Miao M, et al. Complete sequences of mcr-1-harboring plasmids from extended-spectrum-β-lactamase- and carbapenemase-producing *enterobacteriaceae*. *Antimicrob Agents Chemother*. 2016;60(7):4351–4354. doi:10.1128/AAC.00550-16
13. Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Susceptibility Testing Twentieth Informational Supplement*. Wayne, PA: CLSI; 2017.
14. The European Committee on Antimicrobial Susceptibility Testing. *Break-Point Tables for Interpretation of MICs and Zone Diameters*. European Committee on Antimicrobial Susceptibility Testing (EUCAST); 2017.
15. Endimiani A, Carias LL, Hujer AM, et al. Presence of plasmid-mediated quinolone resistance in *Klebsiella pneumoniae* isolates possessing *bla*<sub>KPC</sub> in the United States. *Antimicrob Agents Chemother*. 2008;52(7):2680–2682. doi:10.1128/AAC.00158-08
16. Yang J, Chen Y, Jia X, et al. Dissemination and characterization of NDM-1-producing *Acinetobacter pittii* in an intensive care unit in China. *Clin Microbiol Infect*. 2012;18(12):E506–E513. doi:10.1111/1469-0691.12035
17. Tsakris A, Pournaras S, Woodford N, et al. Outbreak of infections caused by *Pseudomonas aeruginosa* producing VIM-1 carbapenemase in Greece. *J Clin Microbiol*. 2000;38(3):1290–1292.
18. Poirel L, Héritier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother*. 2004;48(1):15–22. doi:10.1128/aac.48.1.15-22.2004



19. Senda K, Arakawa Y, Ichiyama S, et al. PCR detection of metallo-beta-lactamase gene (*bla<sub>IMP</sub>*) in gram-negative rods resistant to broad-spectrum beta-lactams. *J Clin Microbiol.* 1996;34(12):13.
20. Yu Y, Ji S, Chen Y, et al. Resistance of strains producing extended-spectrum beta-lactamases and genotype distribution in China. *J Infect.* 2007;54(1):53–57. doi:10.1016/j.jinf.2006.01.014
21. Pérez-Pérez FJ, Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. *J Clin Microbiol.* 2002;40(6):2153–2162. doi:10.1128/JCM.40.6.2153-2162.2002
22. Diancourt L, Passet V, Verhoef J, Grimont PAD, Brisser S. Multilocus sequence typing of *Klebsiella pneumoniae* nosocomial isolates. *J Clin Microbiol.* 2005;43(8):4178–4182. doi:10.1128/JCM.43.8.4178-4182.2005
23. Quan J, Li X, Chen Y, et al. Prevalence of *mcr-1* in *Escherichia coli* and *Klebsiella pneumoniae* recovered from bloodstream infections in China: a multicentre longitudinal study. *Lancet Infect Dis.* 2017;17(4):400–410. doi:10.1016/S1473-3099(16)30528-X
24. Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. Identification of plasmids by PCR-based replicon typing. *J Microbiol Methods.* 2005;63(3):219–228. doi:10.1016/j.mimet.2005.03.018
25. Johnson TJ, Bielak EM, Fortini D, et al. Expansion of the IncX plasmid family for improved identification and typing of novel plasmids in drug-resistant *Enterobacteriaceae*. *Plasmid.* 2012;68(1):43–50. doi:10.1016/j.plasmid.2012.03.001
26. Logan LK. Carbapenem-resistant *enterobacteriaceae*: an emerging problem in children. *Clin Infect Dis.* 2012;55(6):852–859. doi:10.1093/cid/cis543
27. Yu J, Tan K, Rong Z, et al. Nosocomial outbreak of KPC-2- and NDM-1-producing *Klebsiella pneumoniae* in a neonatal ward: a retrospective study. *BMC Infect Dis.* 2016;16(1):563. doi:10.1186/s12879-016-1987-z
28. Taoufik L, Hanchi AA, Fatiha B, et al. Emergence of OXA-48 carbapenemase producing *Klebsiella pneumoniae* in a neonatal intensive care unit in Marrakech, Morocco. *Clin Med Insights Pediatr.* 2019;13:1179556519834524. doi:10.1177/1179556519834524
29. Tian D, Pan F, Wang C, Sun Y, Zhang H. Resistance phenotype and clinical molecular epidemiology of carbapenem-resistant *Klebsiella pneumoniae* among pediatric patients in Shanghai. *Infect Drug Resist.* 2018;11:1935–1943. doi:10.2147/IDR.S175584
30. Jian Z, Li Y, Liu W, et al. Detection of the novel IMP-38 among carbapenemase-producing *Enterobacteriaceae* in a university hospital, China. *J Infect Dev Ctries.* 2014;8(8):1044–1048. doi:10.3855/jidc.4179
31. Dong F, Lu J, Wang Y, et al. A five-year surveillance of carbapenemase-producing *Klebsiella pneumoniae* in a pediatric Hospital in China reveals increased predominance of NDM-1. *Biomed Environ Sci.* 2017;30(8):562–569. doi:10.3967/bes2017.075
32. Bi R, Kong Z, Qian H, et al. High prevalence of *bla<sub>NDM</sub>* variants among carbapenem-resistant *Escherichia coli* in Northern Jiangsu Province, China. *Front Microbiol.* 2018;9:2704. doi:10.3389/fmicb.2018.02704
33. Nour I, Eldeglia HE, Nasef N, Shouman B, Abdel-Hady H, Shabaan AE. Risk factors and clinical outcomes for carbapenem-resistant Gram-negative late-onset sepsis in a neonatal intensive care unit. *J Hosp Infect.* 2017;97(1):52–58. doi:10.1016/j.jhin.2017.05.025
34. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant *Klebsiella pneumoniae* infection and the impact of antimicrobial and adjunctive therapies. *Infect Control Hosp Epidemiol.* 2008;29(12):1099–1106. doi:10.1086/592412
35. Zhu J, Sun L, Ding B, et al. Outbreak of NDM-1-producing *Klebsiella pneumoniae* ST76 and ST37. *Eur J Clin Microbiol Infect Dis.* 2016;35(4):611–618. doi:10.1007/s10096-016-2578-z
36. Zhang W, Guo Y, Li J, et al. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing *Klebsiella pneumoniae*. *Antimicrob Resist Infect Control.* 2018;7:142. doi:10.1186/s13756-018-0435-9
37. Zheng R, Zhang Q, Guo Y, et al. Outbreak of plasmid-mediated NDM-1-producing *Klebsiella pneumoniae* ST105 among neonatal patients in Yunnan, China. *Ann Clin Microbiol Antimicrob.* 2016;15:10. doi:10.1186/s12941-016-0124-6
38. Nakamura K, Kaneko M, Abe Y, et al. Outbreak of extended-spectrum beta-lactamase-producing *Escherichia coli* transmitted through breast milk sharing in a neonatal intensive care unit. *J Hosp Infect.* 2016;92(1):42–46. doi:10.1016/j.jhin.2015.05.002
39. Wailan AM, Paterson DL, Caffery M, Sowden D, Sidjabat HE. Draft genome sequence of NDM-5-producing *Escherichia coli* sequence type 648 and genetic context of *bla<sub>NDM-5</sub>* in Australia. *Genome Announc.* 2015;3(2):e00194–15. doi:10.1128/genomeA.00194-15
40. Hammerum AM, Hansen F, Olesen B, et al. Investigation of a possible outbreak of NDM-5-producing ST16 *Klebsiella pneumoniae* among patients in Denmark with no history of recent travel using whole-genome sequencing. *J Glob Antimicrob Resist.* 2015;3(3):219–221. doi:10.1016/j.jgar.2015.07.001
41. Baraniak A, Izdebski R, Fiett J, et al. NDM-producing *Enterobacteriaceae* in Poland, 2012–14: inter-regional outbreak of *Klebsiella pneumoniae* ST11 and sporadic cases. *J Antimicrob Chemother.* 2016;71(1):85–91. doi:10.1093/jac/dkv282
42. Pitart C, Solé M, Roca I, et al. Molecular characterization of *bla<sub>NDM-5</sub>* Carried on an IncFII plasmid in an *Escherichia coli* isolate from a nontraveler patient in Spain. *Antimicrob Agents Chemother.* 2015;59(1):659–662. doi:10.1128/AAC.04040-14
43. Nakano R, Nakano A, Hikosaka K, et al. First report of metallo-β-lactamase NDM-5-producing *Escherichia coli* in Japan. *Antimicrob Agents Chemother.* 2014;58(12):7611–7612. doi:10.1128/AAC.04265-14
44. Chen D, Gong L, Walsh TR, et al. Infection by and dissemination of NDM-5-producing *Escherichia coli* in China. *J Antimicrob Chemother.* 2016;71(2):563–565. doi:10.1093/jac/dkv352
45. Zhu YQ, Zhao JY, Xu C, Zhao H, Jia N, Li Y-N. Identification of an NDM-5-producing *Escherichia coli* sequence type 167 in a neonatal patient in China. *Sci Rep.* 2016;6:29934. doi:10.1038/srep29934
46. Kong L, Lei C, Ma S, et al. Various sequence types of *Escherichia coli* isolates coharboring *bla<sub>NDM-5</sub>* and *mcr-1* genes from a commercial swine farm in China. *Antimicrob Agents Chemother.* 2017;61(3):e02167–16. doi:10.1128/AAC.02167-16
47. He T, Wang Y, Sun L, Pang M, Zhang L, Wang R. Occurrence and characterization of *bla<sub>NDM-5</sub>*-positive *Klebsiella pneumoniae* isolates from dairy cows in Jiangsu, China. *J Antimicrob Chemother.* 2017;72(1):90–94. doi:10.1093/jac/dkw357
48. Liu B, Zhang X, Wan S, Hao -J-J, Jiang R-D, Song F-J. Characteristics of carbapenem-resistant *Enterobacteriaceae* in ready-to-eat vegetables in China. *Front Microbiol.* 2018;9:1147. doi:10.3389/fmicb.2018.01147

**Infection and Drug Resistance**

Dovepress

**Publish your work in this journal**

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>